Answers are grounded in this paper and cite their sources.
Network-based prediction reveals doxycycline's potential in reducing Alzheimer's disease incidence in elderly populations, suggesting new treatment options.
Alzheimer's disease (AD), a leading global cause of dementia, disability, and mortality, represents a critical unmet need for effective therapeutic interventions. Drug repurposing offers an expedited pathway to address this challenge compared to traditional drug development. Here, we leveraged network-based prediction and real-world patient data validation, a comprehensive strategy to identify unanticipated therapeutic applications for existing medications. Traumatic brain injury (TBI), a major risk factor for earlier and more severe AD, exhibits heterogenous clinical outcomes influenced by genetic susceptibility, suggesting that TBI-diagnosed populations represent a cohort enriched for neurodegeneration vulnerability. Building on this premise, we integrated network-based multi-omics and endophenotypic disease modules from individuals with TBI and AD histories with large real-world patient data analysis from insurance claims to prioritize repurposable drugs. A network proximity algorithm applied to TBI- and AD-associated gene sets identified statistically ranked candidates, including doxycycline and irbesartan. We then assessed all candidates' AD risk reduction potential using a nationwide Medicare database encompassing nearly 9 million individuals. In a retrospective observational study of AD-free elderly individuals monitored for up to 3 years, propensity-score adjusted survival analyses demonstrated a significantly reduced cumulative incidence of AD in doxycycline and irbesartan-prescribed individuals, with risk ratios of 0.92 and 0.83, respectively, at a 95 % confidence interval. These findings nominate doxycycline and irbesartan as potential repurposable drugs for AD and demonstrate the translational potential of synergizing network-based prediction with real-world patient evidence in drug repurposing for neurodegenerative disease if broadly applied.
No takes yet. Share an insight, caveat, or question.
Bykova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: